OPEN ACCESS Freely available online

ISSN: 2167-1052
Advances in Pharmacoepidemiology and Drug Safety

Commentary

Presentation of the Potential of Glycopeptides: A Unique Class of Antibiotics in the Fight against Antibiotic Resistance

Rosa Lapal*

Department of Engineering and Health, University of Southern Queensland, Queensland, Australia

DESCRIPTION

Antibiotic resistance has emerged as a global health crisis, necessitating the development of novel therapeutic strategies to combat infectious diseases. In this regard, glycopeptides have garnered considerable attention due to their unique chemical structure and potent antimicrobial activity. Glycopeptides are a class of antibiotics characterized by the presence of a glycosylated amino acid residue, which imparts their distinctive properties.

The history of glycopeptides dates back to the 1950s when researchers discovered the first member of this class, vancomycin, from a soil sample. Initially, vancomycin was primarily used as a "last resort" antibiotic for treating multidrug-resistant Gram-positive bacterial infections. However, its limited spectrum of activity and the emergence of vancomycin-resistant strains led to the exploration of other glycopeptides, such as teicoplanin and dalbavancin.

Chemical structure and mechanism of action

Glycopeptides possess a complex chemical structure, consisting of a cyclic peptide backbone attached to a sugar moiety. The sugar component, usually N-acetylglucosamine or N-acetylmuramic acid, contributes to the specific interaction of glycopeptides with bacterial cell wall precursors. The mode of action of glycopeptides involves binding to the D-Ala-D-Ala terminus of the peptidoglycan precursor, inhibiting its incorporation into the growing cell wall. This interference weakens the structural integrity of the bacterial cell wall, leading to cell lysis and ultimately bacterial death.

Therapeutic applications

Glycopeptides have shown remarkable efficacy against Gram-positive pathogens, particularly Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant *Enterococci.*

Vancomycin, the prototypical glycopeptide, is commonly used in the treatment of severe infections caused by these resistant strains. Teicoplanin, another glycopeptide, offers a broader spectrum of activity and is often preferred in certain clinical scenarios. The use of glycopeptides extends beyond traditional antibiotic therapy, as their anti-inflammatory and immunomodulatory properties have shown promise in the treatment of inflammatory bowel diseases and certain cancers. Despite their effectiveness, the emergence of glycopeptide-resistant strains poses a significant challenge. Vancomycin-intermediate *S. aureus* (VISA) and vancomycin-resistant *S. aureus* (VRSA) strains have been reported, necessitating the development of alternative treatment options. Researchers are actively exploring strategies to overcome resistance, including the development of novel glycopeptide derivatives, combination therapies, and the use of adjuvants to enhance antibacterial activity.

Future prospects and innovations

The future of glycopeptides holds immense potential for innovation and development. Scientists are investigating the modification of glycopeptide structures to enhance their antibacterial activity, expand their spectrum of action, and overcome resistance mechanisms. Additionally, advances in synthetic biology and genetic engineering have paved the way for the production of engineered glycopeptides with improved pharmacokinetic properties and reduced toxicity. Researchers are exploring their potential as drug delivery vehicles, using their cell wall-targeting properties to specifically transport therapeutics to bacterial cells. Furthermore, the immunomodulatory effects of glycopeptides have sparked interest in their potential for immune therapies. Overall, glycopeptides represent a significant area of research and development in the fight against infectious diseases. Their unique chemical structure, mechanism of action, and potential for immunomodulation make them versatile therapeutic agents. Ongoing efforts to enhance their antibacterial activity, broaden their spectrum of action, and overcome resistance mechanisms hold promise for the future. With continued innovation and exploration, glycopeptides have the potential to revolutionize the treatment of bacterial infections and contribute to the development of novel therapies for a range of diseases.

Correspondence to: Rosa Lapal, Department of Engineering and Health, University of Southern Queensland, Queensland, Australia E-mail: rosa.lap21@gmail.com

Received: 10-May-2023, Manuscript No. PDS-23-21746; **Editor assigned:** 15-May-2023, Pre QC No. PDS-23-21746 (PQ); **Reviewed:** 29-May-2023, QC No. PDS-23-21746; **Revised:** 06-Jun-2023, Manuscript No PDS-23-21746 (R); **Published:** 13-Jun-2023, DOI: 10.35248/2167-1052.23.12.316

Citation: Lapal R (2023) Presentation of the Potential of Glycopeptides: A Unique Class of Antibiotics in the Fight against Antibiotic Resistance. Adv Pharmacoepidemiol Drug Saf. 12:316.